SUMMARY: The Messolonghi-Etoliko lagoon is one of the largest lagoon system in the northern Mediterranean coast. This area contains six clearly distinct lagoons with different topographic and hydrological features. The fishery landings of the lagoons are based on the ontogenic and seasonal migrations of the species. The total annual fishery landings of the barrier fish traps are estimated as 195 mt and are mainly composed of 16 species belonging to 8 families. Eel (Anguilla anguilla), the four species of Mugilidae (Liza saliens, L. aurata, L. ramada and Mugil cephalus), the two species of Sparidae (Sparus aurata and Diplodus annularis) and one species of Mullidae (Mullus barbatus) represent more than 92% of the total annual landings. The composition of the fishery landings varies between lagoons. The cluster analysis showed three groups of lagoons. The first group comprised lagoons in which the landings were dominated by eel, the second group was dominated by Mugilidae species and S. aurata, and the third by L. ramada and M. cephalus. The diversity index of the fishery landings is fairly constant in time, except for the Etoliko lagoon, where repeated anoxic crises decreased the diversity index value to almost zero in 1992. All the landing series showed a dominant annual cycle. Two seasonal patterns of the fishery landings were observed and linked to the fish spawning behaviour and/or their reaction to environmental forcings. The first one concerns species caught from summer to early autumn and the second pattern concerns species trapped during their autumn to winter offshore migration.Key words: Mediterranean lagoon, fisheries landings, fish diversity, spatial pattern, seasonal fluctuations.
RESUMEN: VARIACIONES GEOGRÁFICAS DE LA PRODUCCIÓN PISCÍCOLA DE LA FORMACIÓN DE MARISMAS DE MESOLOGI-ETO-LIKÓ (GRECIA OCCIDENTAL). -La formación de lagunas de Mesologi-Etolikó es una de las reservas naturales marinas más grandes de la franja septentrional del Mediterráneo. Este conjunto está compuesto por seis distintas marismas, con diferentes características topográficas e hidrográficas cada una de ellas. La producción piscícola de las marismas se basa en los movimientos estacionales de las especies hacia el mar. Del estudio del trampeo se concluye que los movimientos migratorios equivalen a 195 toneladas y se componen principalmente de 16 especies las cuales pertenecen a 8 familias: anguila (Anguilla anguilla), cuatro especies de Mugilidae (Liza saliens, L. aurata, L. ramada, y Mugil cephalus), dos especies de Sparidae (Sparus aurata y Diplodus annularis) y una especie de Mullidae (Mullus barbatus). Estas especies representan más del 92% de los desplazaminentos anuales. Estos varían entre las distintas marismas. El análisis cluster distingue tres tipos de marismas. El primer grupo incluye las marismas cuyos movimientos son principalmente de anguila; el segundo grupo de Mugilidae y de S. aurata, y el tercero con movimientos sobre todo de L. ramada y M. cephalus. Los desplazamientos de estas especies presentan un ciclo anual...
IntroductionThe purpose of the study was to evaluate the long-term anatomical and functional outcomes in patients with diabetic macular edema (DME) treated with intravitreal dexamethasone implant and to determine the predictive factors for the final visual outcome.MethodsThe study included 54 patients with DME refractory to previous antivascular endothelial growth factor (anti-VEGF) who were treated with intravitreal dexamethasone implant. Predictive factors for visual outcome were assessed. In addition, the change in best-corrected visual acuity (BCVA) and the percentage of patients with edema resolution were evaluated.ResultsAt the end of the 12-month follow-up, patients with DME gained + 5.2 letters (about 1 Snellen line), while 57.4% of patients presented total resolution of macular edema. Negative predictive factors for the final visual outcome were found to be increasing age, increasing macular thickness, phakic status, the presence of intraretinal fluid, hyperreflective foci, hard exudates, as well as external limiting membrane and ellipsoid zone disruption. The mean number of injections was 2.1.ConclusionsThe various predictive factors that determine the visual outcome and possibly define patient prognosis after dexamethasone intravitreal implant in DME cases have been studied. The long follow-up showed that dexamethasone intravitreal implant seems to be a safe and effective treatment for this disease, requiring a limited number of injections.
Thirty outpatients meeting DSM-III-R or DSM-IV criteria for major depression, single or recurrent episode, and failing to respond to an adequate trial of an antidepressant (>6 weeks at recommended dosage) received buspirone (20-30 mg/day) for 4 or 5 weeks in addition to their existing antidepressant. Of the 22 patients who had buspirone added to their selective serotonin reuptake inhibitor antidepressant regimen (fluoxetine, paroxetine, or citalopram), 59% (13/22) showed complete or partial remission of their depressive symptomatology. Similarly, 63% (5/8) of patients treated with buspirone in addition to clomipramine showed complete or partial remission. The mean score on the Clinical Global Impressions Scale fell by 64% (from 4.7 to 1.7; p < 0.0001) in treatment responders (complete and partial). No serious side effects were observed during combination therapy. Seventy-nine percent (11/14) of initial responders (both complete and partial) who remained on augmentation therapy for at least 4 months were symptom-free at follow-up. Buspirone augmentation may produce marked clinical improvement in depressed patients who are initially unresponsive to standard antidepressant therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.